BusinessSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDIBy Nasdaq OMXDec 21, 2017, 7:00 AM UTC
BusinessSummit Therapeutics to Present at the Canaccord Genuity Growth ConferenceBy Nasdaq OMXAug 3, 2017, 11:00 AM UTC
